Amino Up Chemical Co., Ltd.

Kansai Medical University

The Ritsumeikan Trust

Zeria Pharmaceutical Co., Ltd.

Amino Up Co., Ltd.

Mikio Nishizawa

Takehito Miura

Tadayoshi Okumura

Yasuo Kamiyama

Koji Wakame

Yoshiya Tahashi

Keiko Inoue, Legal Representative

Junichi Fujisawa

Katsunori Yoshida

Hideo Yamagata

Shigeo Mori

Yasushi Sugano

Fukiko Furukawa

Yukinobu Ikeya

Masanori Matsushita

Toshihito Seki

Koichi Matsuzaki

A compound is represented by Formula (I) or (II) described below. A medicine includes, as an active ingredient, a compound represented by Formula (I), (II), or (III) described below. 

Compound, medicine, anti-inflammatory, cosmetic, food and drink, and method for producing compound

The invention relates to sense oligonucleotide having a sequence complementary to a single-stranded RNA (antisense transcript) having a sequence complementary to mRNA of iNOS gene in order to control expression of iNOS (inducible nitric oxide synthase). The sense oligonucleotide of the present invention can control expression of iNOS and is useful for biological defense and treatment and prevention of diseases related to excessive production of NO, such as cancerogenesis, inflammatory disease, endotoxin shock by bacterial infection and the like.

Sense oligonucleotide capable of controlling the expression of INOS and composition comprising the same

The invention relates to a method of intracellularly controlling amounts of gene products, which can increase an amount of gene product intracellularly, comprising a step of introducing into the cell a substance having a sequence complementary to the base sequence of mRNA corresponding to the gene product, its precursor or another substance which can have equivalent action in the cell.

Method for controlling the amount of gene product, and agent for controlling the amount of gene product

Sense oligonucleotide capable of controlling the expression of iNOS and composition comprising the same

Polyclonal antibody specific for a phosphorylated linker region in Smad2 and/or Smad3.

Antibodies specific for phosphorylation sites and screening methods using the same antibodies

Growing community of inventors

Ibaraki, Japan

Mikio Nishizawa